Indoco Remedies Ltd
Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).[1]
- Market Cap ₹ 2,854 Cr.
- Current Price ₹ 309
- High / Low ₹ 388 / 190
- Stock P/E
- Book Value ₹ 111
- Dividend Yield 0.48 %
- ROCE -0.48 %
- ROE -7.00 %
- Face Value ₹ 2.00
Pros
- Company's working capital requirements have reduced from 61.0 days to 38.6 days
Cons
- Stock is trading at 2.79 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 8.51% over past five years.
- Company has a low return on equity of 5.08% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
731 | 854 | 1,005 | 1,071 | 1,041 | 968 | 1,107 | 1,242 | 1,541 | 1,669 | 1,817 | 1,665 | 1,671 | |
610 | 689 | 834 | 914 | 906 | 892 | 983 | 1,017 | 1,213 | 1,381 | 1,572 | 1,566 | 1,602 | |
Operating Profit | 120 | 166 | 171 | 157 | 135 | 77 | 123 | 225 | 328 | 288 | 245 | 99 | 69 |
OPM % | 16% | 19% | 17% | 15% | 13% | 8% | 11% | 18% | 21% | 17% | 13% | 6% | 4% |
2 | 2 | 1 | 4 | 5 | 6 | 2 | 3 | 2 | 1 | 20 | 6 | 7 | |
Interest | 19 | 11 | 12 | 6 | 24 | 21 | 26 | 22 | 14 | 25 | 38 | 66 | 78 |
Depreciation | 31 | 47 | 61 | 63 | 68 | 72 | 71 | 73 | 79 | 71 | 92 | 114 | 116 |
Profit before tax | 72 | 110 | 99 | 91 | 48 | -9 | 29 | 132 | 237 | 193 | 136 | -74 | -118 |
Tax % | 20% | 24% | 17% | 15% | 15% | -69% | 16% | 30% | 35% | 26% | 29% | 5% | |
58 | 83 | 82 | 77 | 41 | -3 | 24 | 93 | 155 | 142 | 97 | -78 | -116 | |
EPS in Rs | 6.29 | 8.99 | 8.89 | 8.36 | 4.47 | -0.31 | 2.62 | 10.10 | 16.80 | 15.44 | 10.68 | -7.99 | -12.16 |
Dividend Payout % | 22% | 18% | 18% | 19% | 22% | -95% | 11% | 15% | 13% | 15% | 14% | -2% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 9% |
3 Years: | 3% |
TTM: | -8% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -269% |
Stock Price CAGR | |
---|---|
10 Years: | -1% |
5 Years: | 5% |
3 Years: | -8% |
1 Year: | -5% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 9% |
3 Years: | 5% |
Last Year: | -7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
Reserves | 439 | 500 | 558 | 633 | 657 | 642 | 661 | 751 | 886 | 1,010 | 1,091 | 1,004 |
92 | 97 | 140 | 280 | 282 | 296 | 262 | 267 | 257 | 333 | 672 | 994 | |
180 | 230 | 224 | 266 | 281 | 301 | 330 | 279 | 325 | 297 | 363 | 414 | |
Total Liabilities | 729 | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 |
325 | 340 | 374 | 440 | 489 | 468 | 590 | 570 | 555 | 678 | 954 | 1,041 | |
CWIP | 44 | 63 | 55 | 91 | 136 | 185 | 51 | 68 | 122 | 114 | 125 | 276 |
Investments | 0 | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 9 | 1 |
360 | 443 | 496 | 666 | 613 | 605 | 631 | 677 | 809 | 864 | 1,057 | 1,111 | |
Total Assets | 729 | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
99 | 109 | 112 | 89 | 123 | 132 | 123 | 82 | 174 | 179 | 157 | 94 | |
-41 | -88 | -111 | -171 | -135 | -104 | -56 | -67 | -121 | -208 | -433 | -339 | |
-59 | -20 | -2 | 132 | -39 | -16 | -64 | -30 | -44 | 23 | 280 | 241 | |
Net Cash Flow | -1 | 1 | -0 | 50 | -51 | 12 | 3 | -14 | 8 | -7 | 4 | -4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 69 | 66 | 69 | 74 | 73 | 74 | 69 | 69 | 70 | 77 | 82 | 77 |
Inventory Days | 148 | 181 | 174 | 189 | 203 | 209 | 230 | 245 | 248 | 228 | 230 | 307 |
Days Payable | 95 | 146 | 137 | 166 | 157 | 195 | 183 | 117 | 107 | 86 | 100 | 152 |
Cash Conversion Cycle | 122 | 102 | 105 | 97 | 119 | 88 | 116 | 197 | 212 | 219 | 212 | 232 |
Working Capital Days | 44 | 46 | 48 | 41 | 38 | 21 | 22 | 59 | 78 | 82 | 62 | 39 |
ROCE % | 17% | 21% | 17% | 12% | 7% | 1% | 6% | 16% | 23% | 17% | 10% | -0% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
20h - Sale and leaseback of movable assets at Waluj for Rs.27.21 Cr; 10-year lease fees Rs.37.98 Cr.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - Read with Para A of Part A of Schedule III of the SEBI (LODR) Regulation 2015, we wish to inform you that the senior management …
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
28 Jul - Q1 FY '26 results: EBITDA improved, OTC up 46%, partial US FDA clearance, Europe GMP approval, debt Rs.950 Cr.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
25 Jul - Newspaper publication of Unaudited Standalone and consolidated Financial Results for the quarter ended 30-06-2025
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
24 Jul - Audio recording of Q1 FY2026 earnings call available on company website.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Jul 2025TranscriptPPT
-
May 2025Transcript PPT
-
Jan 2025TranscriptPPT
-
Oct 2024Transcript PPT
-
Jul 2024TranscriptPPT
-
Jun 2024Transcript PPT REC
-
Jan 2024TranscriptPPT
-
Oct 2023TranscriptPPT
-
Jul 2023TranscriptPPT
-
May 2023TranscriptPPT
-
Jan 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
Jun 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Aug 2018TranscriptPPT
Business Segments
A) Domestic Formulations (48% of FY24 revenue)[1]
Indoco Remedies Ltd holds a strong foothold across various therapeutic categories, including Gastroenterology, Dentistry & Stomatology, Respiratory, Diabetology, Women's Health, Nutritional Products, Cardiology, Metabolic Disorders, and Primary Care medicines. In FY24, the domestic business crossed 1,280 Cr, ranking 31st in India (IQVIA MAT 2023-24). The company enjoys prescription patronage from over 240,000 prescribers, with 106 million prescriptions annually, and ranks 22nd in the Indian Pharmaceutical Market (IQVIA). It has 45 products ranking among the top 5 in their respective sub-segments.